Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CHEK1 positive |
| Therapy | Prexasertib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CHEK1 positive | lung non-small cell carcinoma | predicted - sensitive | Prexasertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Prexasertib (LY2606368) increased apoptosis of non-small cell lung cancer (NSCLC) cells in culture, and inhibited Chek1 phosphorylation, induced DNA damage, and reduced tumor growth in a NSCLC cell line xenograft model (PMID: 26141948). | 26141948 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26141948) | LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. | Full reference... |